<div id="readability-page-1"><p>Principal Financial Group Inc. lowered its position in shares of  Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 12.9% in the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  owned 482,247 shares of the biopharmaceutical company's stock after selling 71,315 shares during the quarter. Principal Financial Group Inc. owned 0.41% of Dynavax Technologies worth $4,789,000 at the end of the most recent quarter.</p><p>A number of other hedge funds have also recently bought and sold shares of DVAX. Osaic Holdings Inc. lifted its holdings in  Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares during the last quarter.  Summit Global Investments acquired a new stake in  Dynavax Technologies during the third quarter valued at approximately $113,000.  Catalyst Funds Management Pty Ltd bought a new stake in  Dynavax Technologies during the second quarter worth approximately $121,000.  VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in  Dynavax Technologies in the third quarter worth approximately $122,000.  Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of  Dynavax Technologies in the second quarter valued at $127,000. 96.96% of the stock is owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Dynavax Technologies</strong> alerts:</span></p></div><h2>Dynavax Technologies Stock Performance</h2><p>Shares of Dynavax Technologies stock opened at $15.50 on Monday. The stock has a market cap of $1.82 billion, a PE ratio of -41.89 and a beta of 0.97. The business has a fifty day simple moving average of $14.40 and a 200-day simple moving average of $11.82. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $15.73. </p><h2>Insider Activity at Dynavax Technologies</h2><p>In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares in the company, valued at approximately $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Corporate insiders own  2.98% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages have recently commented on DVAX. Weiss Ratings  reiterated a &#34;sell (d)&#34; rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Wall Street Zen raised Dynavax Technologies to a &#34;strong-buy&#34; rating in a report on Saturday. Finally, William Blair cut Dynavax Technologies from an &#34;outperform&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one  has given a Hold rating and two have assigned  a Sell rating to the stock. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Hold&#34; and a consensus price target of $24.33.</p><p><b>Read Our Latest Research Report on DVAX</b></p><h2>About Dynavax Technologies</h2> (Free Report)<p>Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.  </p><p>Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Dynavax Technologies</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li><li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li><li>URGENT: Sell this stock immediately</li><li>They just tried to kill gold</li><li>Your Bank Account Is No Longer Safe</li></ul><p><strong>Want to see what other hedge funds are holding DVAX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dynavax Technologies Right Now?</h2><p>Before you consider Dynavax Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p><p>While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

IBBQ

DVAX

<p>Principal Financial Group Inc. reduced its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 12.9% in Q3, now holding 482,247 shares valued at $4.79 million. Other hedge funds have also adjusted their positions. The stock opened at $15.50, with a market cap of $1.82 billion. Analysts have mixed ratings on DVAX, with a consensus rating of "Hold" and a price target of $24.33. Dynavax focuses on developing vaccines and immunotherapies, including its FDA-approved hepatitis B vaccine, HEPLISAV-B.</p>

Market Beat

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Dynavax Tech

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Dynavax Technologies Corporation $DVAX Stock Position Lowered by Principal Financial Group Inc.